title: Developing second generation antibody-drug conjugates: the quest for new technologies.
abstract: The field of antibody-drug conjugates (ADCs) has gained significant momentum after the recent regulatory approval of two ADCs, and significant research efforts are directed to identify more effective payloads and simplify current manufacturing challenges.
authors.affiliation: Lead Generation to Compound Realization, Sanofi-Aventis , 94400 Vitry sur Seine, France.
authors.forename: Carlos
authors.initials: C
authors.lastname: Garcia-Echeverria
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology; D055808:Drug Discovery; D006801:Humans; D018796:Immunoconjugates / Q000494:pharmacology*; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018796:Immunoconjugates; D000068878:Trastuzumab